Body weight variation and control of cardiovascular risk factors in essential hypertension.

The objective was to assess the impact of weight changes on blood pressure (BP), lipids and glucose goals in a cohort of hypertensive subjects.Prospective follow-up.Hypertension clinic.326 hypertensive non-diabetic subjects, 46% with metabolic syndrome (MS).Usual care treatment, which included diet, physical exercise and drugs prescribed when indicated. All patients were observed for up to 1 year.BP and low-density lipoprotein-cholesterol (LDL-C) goal were those in ESH/ESC and ATP III recommendations, respectively. The glucose goal was to delay progression to type 2 diabetes mellitus, or to achieve blood glucose100 mg/dl for non-diabetics. According to body weight changes, patients were cat…

[Central blood pressure and vascular damage].

Abstract Background and objective The aim of this study was to assess the relationship between central blood pressure and vascular damage. Patients and methods This cross-sectional study involved 393 never treated hypertensive patients (166 women). Clinical blood pressure (BP), 24 h blood pressure (BP 24 h ) and central blood pressure (CBP) were measured. Vascular organ damage (VOD) was assessed by calculating the albumin/creatinine ratio (ACR), wave pulse pressure velocity and echocardiographic left ventricular mass index (LVMI). Results Patients with VOD had higher values of BP, BP 24 h , and CBP than patients without ACR. When comparing several systolic BP, systolic BP 24 h had a higher …

Uso de espironolactona o doxazosina en pacientes con hipertensión arterial refractaria

Introduccion y objetivos. Valorar el uso de espironolactona o doxazosina en el tratamiento de pacientes con hipertension refractaria (HTAR). Metodos. Estudio retrospectivo comparativo de 181 pacientes con HTAR (pacientes tratados con tres farmacos, uno de ellos diuretico, sin alcanzar el control de la presion arterial [PA]) a quienes se anadio espironolactona (88 casos) o doxazosina (93 casos). Resultados. La PA sistolica (PAS) se redujo 28 mmHg (intervalo de confianza [IC] del 95%, 24-32 mmHg; p < 0,001), y la PA diastolica (PAD), 12 mmHg (IC del 95%, 9-14 mmHg; p < 0,001) en los tratados con espironolactona, y 16 mmHg (IC del 95%, 13-20 mmHg; p < 0,001) y 7 mmHg (IC del 95%, 5-9 mmHg; p <…

Respuesta antihipertensiva a la espironolactona en pacientes con hipertensión arterial refractaria

Fundamento y objetivo Valorar el efecto de anadir espironolactona al tratamiento de pacientes con hipertension arterial (HTA) refractaria e intentar caracterizar a los que consiguen buena respuesta. Pacientes y metodo Se ha realizado un estudio observacional y retrospectivo en pacientes con HTA refractaria –definidos como tratados con 3 farmacos a las dosis habituales, uno de ellos diuretico, sin alcanzar el control de la presion arterial (PA)– y valores de creatinina inferiores a 1,6 mg/dl en varones y a 1,4 mg/dl en mujeres. Resultados A un total de 95 pacientes (un 70% varones y un 40% diabeticos), con una edad media (desviacion estandar) de 66 (12) anos, se les anadio espironolactona al…

Eplerenona en hipertensión arterial resistente con intolerancia previa a espironolactona